Try our beta test site
473 studies found for:    PD-1
Show Display Options
Rank Status Study
21 Recruiting A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma.
Condition: Melanoma
Intervention: Radiation: stereotactic body radiotherapy
22 Completed Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
Condition: Neoplasms by Site
Interventions: Biological: Denenicokin;   Biological: Nivolumab
23 Recruiting Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1
Condition: Cancer
Interventions: Other: Biological samples;   Drug: Anti PD1/PDL1 treatment
24 Completed PD-1/PD-L1 Pathway Study on Septic Patients
Condition: Sepsis
Intervention:
25 Recruiting Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Radiation: Radiotherapy;   Biological: Rituximab;   Biological: Autologous dendritic cells;   Biological: GM-CSF;   Biological: Pembrolizumab
26 Recruiting A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade
Condition: Advanced or Unresectable Melanoma Progressing After PD1 Blockade
Interventions: Biological: ONCOS-102;   Drug: Cyclophosphamide;   Drug: Pembrolizumab
27 Suspended Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: CT-011 (Anti-PD1 Antibody);   Other: Sipuleucel-T (Provenge);   Drug: Cyclophosphamide
28 Recruiting Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
Conditions: Melanoma (Skin);   Skin Cancer
Interventions: Drug: Nivolumab;   Procedure: Surgery to Remove Tumor for Growth of TIL;   Drug: CD137;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: TIL Infusion;   Drug: Interleukin-2
29 Active, not recruiting 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: MK-3475;   Drug: Pomalidomide;   Drug: Dexamethasone
30 Not yet recruiting Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
Condition: Carcinoma, Renal Cell
Interventions: Drug: Nivolumab;   Radiation: Radiation
31 Recruiting A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)
Condition: Advanced Melanoma
Intervention: Drug: Pembrolizumab
32 Recruiting Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475
Conditions: Breast Neoplasms;   Bone Neoplasms
Interventions: Radiation: Stereotactic Ablative Body Radiosurgery (SABR);   Drug: MK-3475
33 Not yet recruiting Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
Conditions: Carcinoma, Non-small-cell Lung;   Mesothelioma;   Pancreatic Neoplasms
Interventions: Drug: Defactinib;   Drug: Pembrolizumab
34 Not yet recruiting Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer
Condition: Renal Cell Carcinoma
Interventions: Drug: Interleukin-2;   Drug: Nivolumab
35 Active, not recruiting Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)
Conditions: Influenza Virus Vaccine Adverse Reaction (Disorder);   Influenza;   Malignancy
Intervention: Biological: influenza vaccination
36 Recruiting Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Condition: Neoplasms by Site
Interventions: Biological: BMS-986016;   Biological: BMS-936558
37 Active, not recruiting Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: NY-ESO-1 157-165 (165V);   Drug: Nivolumab;   Biological: gp100:280-288 (288V);   Drug: Montanide ISA 51 vegetable grade (VG);   Drug: Ipilimumab;   Procedure: Apheresis Procedure
38 Not yet recruiting RADVAX™: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy
Condition: Urothelial Cancer
Interventions: Drug: PEMBROLIZUMAB;   Radiation: hypofractionated radiation
39 Active, not recruiting A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)
Condition: Advanced Solid Tumors
Interventions: Drug: PF-05082566;   Drug: MK-3475
40 Recruiting Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody
Condition: Melanoma
Intervention: Drug: Pembrolizumab and Ipilimumab combination

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.